Home > Insider Trading > Filing (0001415889-24-009629)

Filing Details

Accession Number:: 0001415889-24-009629
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-01 21:31:38
Reporting Period:: 2024-03-28

Accepted Time:: 2024-04-01 21:31:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1477123	Mitchell Lloyd Segal	C/O Repare Therapeutics Inc. St-Laurent A8 H4S 1Z9	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2024-03-28	2,650	$4.62	110,049	No	4	S	Indirect	See footnote
Common Shares	Disposition	2024-04-01	2,491	$4.63	107,558	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	102,678	Direct

Footnotes

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13.
These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive.
Includes 1,217 shares, 967 shares and 2,000 shares acquired on February 15, 2023, August 15, 2023 and February 15, 2024, respectively, under the Issuer's employee stock purchase plan.